Antitumor Activity of Silver Nanoparticles and Its Implications on Global Health
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: closed (25 August 2023) | Viewed by 5183
Special Issue Editors
Interests: nanotoxicology; nanomedicine; cancer; drug development
Special Issues, Collections and Topics in MDPI journals
Interests: metal-based drugs; cancer; nanomaterials; medicinal chemistry
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Silver nanoparticles are among the most studied particles due to their biomedical properties in regard to cancer treatment. Several research groups have worked on determining the potential application of silver nanoparticles, their relationship with their physicochemical properties, and their possible adverse effects, among other things, in order to arrive at an alternative treatment as a viable solution for cancer. However, the international scientific community is still concerned about finding the most effective and efficient methods to establish clear cost/benefit ratios. In addition, the regulations regarding the use of silver nanoparticles for biomedical treatment are still under development, which poses a greater challenge.
This Special Issue highlights the research and development of silver nanoparticles with a focus on cancer treatment. It contemplates in vivo, in vitro, and in silico models to evaluate effectiveness as well as toxicity, genotoxicity, and teratogenicity, which contribute to the knowledge of the antitumor activity of silver nanoparticles and its implications in global health.
Dr. Yanis Toledano-Magaña
Dr. Juan Carlos García-Ramos
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- silver nanoparticles
- antitumor activity
- cytotoxicity
- genotoxicity
- in silico approaches
- normativity and guidelines
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
